person · Reporting owner
VON RICKENBACH JOSEF H
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rein Therapeutics, Inc.RNTX · Entity 7071 | Director | May 21, 2026 | May 29, 2026 |
| Xos, Inc.NGAC · Entity 7263 | Director | October 06, 2020 | October 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rein Therapeutics, Inc.
Report date May 21, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock , $0.001 par valueSEC Table I · non-derivative | Direct | 62,514 |
Last balance in matching sequence
After 2026-05-27 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2026-05-21 · Purchase · Acquired 3,420 · Balance 18,874 F1: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Row 2 · 2026-05-22 · Purchase · Acquired 15,950 · Balance 34,824 F1: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Row 3 · 2026-05-26 · Purchase · Acquired 23,190 · Balance 58,014 F1: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Row 4 · 2026-05-27 · Purchase · Acquired 4,500 · Balance 62,514 F1: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1).
Xos, Inc.
Report date October 06, 2020 · Filed October 06, 2020
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PAREXEL INTERNATIONAL CORP
Report date September 29, 2017 · Filed October 04, 2017
Section 16 reporting ended · disclosed 2017-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 1
1 source rowRow 1 · 2017-09-29 · Disposition to issuer · Disposed 503,329 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.00 · Expires 2024-09-14 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-09-29 · Other · Disposed 50,800 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F3: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/14/2016. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.58 · Expires 2023-09-09 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-09-29 · Other · Disposed 95,000 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F4: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/09/2015. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.93 · Expires 2022-09-10 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-09-29 · Other · Disposed 93,300 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F5: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/10/2014. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.69 · Expires 2021-09-11 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-09-29 · Other · Disposed 73,500 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F6: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/11/2013. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.64 · Expires 2020-09-19 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-09-29 · Other · Disposed 108,800 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F7: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/19/2012. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.26 · Expires 2019-09-21 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-09-29 · Other · Disposed 151,700 · Balance 0 F2: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F8: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/21/2011. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-12-31 | Direct | 29,600 |
Reported balance
After 2017-09-29 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-09-29 · Other · Acquired 29,600 · Balance 29,600 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-12-31 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-09-29 · Other · Disposed 29,600 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-12-31 | Direct | 14,800 |
Reported balance
After 2017-09-29 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-09-29 · Other · Acquired 11,988 · Balance 14,800 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. F11: These restricted stock units were to vest in full on 09/14/2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-12-31 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2017-09-29 · Other · Disposed 14,800 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. F10: These restricted stock units were to vest in full on September 9, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-12-31 | Direct | 21,015 |
Reported balance
After 2017-09-29 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2017-09-29 · Other · Acquired 15,960 · Balance 21,015 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-12-31 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2017-09-29 · Other · Disposed 21,015 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-12-31 | Direct | 9,000 |
Reported balance
After 2017-09-29 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2017-09-29 · Other · Acquired 5,700 · Balance 9,000 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. F12: These restricted stock units were to vest in full on 09/09/2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-12-31 | Direct | 0 |
Reported balance
After 2017-09-29 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-09-29 · Other · Disposed 9,000 · Balance 0 F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration").
F2: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time.
F3: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/14/2016.
F4: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/09/2015.
F5: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/10/2014.
F6: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/11/2013.
F7: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/19/2012.
F8: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/21/2011.
F9: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration.
F10: These restricted stock units were to vest in full on September 9, 2018.
F11: These restricted stock units were to vest in full on 09/14/2019.
F12: These restricted stock units were to vest in full on 09/09/2018.
Virgin Orbit Holdings, Inc.
Report date December 29, 2021 · Filed January 04, 2022
Section 16 reporting ended · disclosed 2022-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2021-12-29 transaction · row 1
1 source rowRow 1 · 2021-12-29 · Grant · Acquired 125,000 · Balance 125,000 F1: Reflects Issuer's common stock acquired from the Issuer pursuant to a Subscription Agreement in connection with the business combination of NextGen Acquisition Corp. II (the former name of the Issuer) and Virgin Orbit Holdings, Inc. (formerly known as Virgin Orbit) (such business combination, the "Business Combination"), which closed on December 29, 2021. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Issuer's common stock acquired from the Issuer pursuant to a Subscription Agreement in connection with the business combination of NextGen Acquisition Corp. II (the former name of the Issuer) and Virgin Orbit Holdings, Inc. (formerly known as Virgin Orbit) (such business combination, the "Business Combination"), which closed on December 29, 2021. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 00:15 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | PurchaseCommon stock , $0.001 par value | 4,500 | $1.07 | $4,818.60 |
DisclosureSEC source: 0001193125-26-245832 · ownership.xml · nonDerivative · entry 4 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,514 F1 · shares: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). F1 · balance_after: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| May 26, 2026 Filed May 29, 2026 00:15 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | PurchaseCommon stock , $0.001 par value | 23,190 | $1.06 | $24,470.09 |
DisclosureSEC source: 0001193125-26-245832 · ownership.xml · nonDerivative · entry 3 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,014 F1 · shares: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). F1 · balance_after: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| May 22, 2026 Filed May 29, 2026 00:15 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | PurchaseCommon stock , $0.001 par value | 15,950 | $1.05 | $16,707.63 |
DisclosureSEC source: 0001193125-26-245832 · ownership.xml · nonDerivative · entry 2 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,824 F1 · shares: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). F1 · balance_after: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| May 21, 2026 Filed May 29, 2026 00:15 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | PurchaseCommon stock , $0.001 par value | 3,420 | $1.04 | $3,564.32 |
DisclosureSEC source: 0001193125-26-245832 · ownership.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,874 F1 · shares: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). F1 · balance_after: The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| July 23, 2025 Filed Jul 23, 2025 23:40 UTC | Rein Therapeutics, Inc. RNTX · Entity 7071 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000950170-25-098044 · ownership.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-07-22 F1 · derivative.exercise_date: This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| December 02, 2024 Filed Dec 6, 2024 21:34 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0000950170-24-134152 · ownership.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-12-01 F1 · derivative.exercise_date: This option was granted on December 2, 2024. The shares underlying the option are scheduled to vest in full on December 2, 2025. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:07 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000950170-24-099838 · ownership.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-08-19 F1 · derivative.exercise_date: This option was granted on August 20, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) August 20, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:05 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0000950170-24-023839 · ownership.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-02-27 F1 · derivative.exercise_date: This option was granted on February 28, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) February 28, 2025 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| February 28, 2024 Filed Apr 10, 2024 20:15 UTC Amendment | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0000950170-24-043362 · ownership.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common Stock · 2,725 shares Expires 2034-02-27 F1 · derivative.exercise_date: This option was granted on February 28, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) February 28, 2025 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:16 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 54,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0000899243-22-023144 · doc4.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Common Stock · 54,500 shares Expires 2032-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| December 29, 2021 Filed Jan 4, 2022 00:41 UTC | Virgin Orbit Holdings, Inc. VORB · Entity 114569 | GrantCommon Stock | 125,000 | $10.00 | $1,250,000.00 |
DisclosureSEC source: 0001213900-22-000310 · ownership.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · FORMER DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · kind: Reflects Issuer's common stock acquired from the Issuer pursuant to a Subscription Agreement in connection with the business combination of NextGen Acquisition Corp. II (the former name of the Issuer) and Virgin Orbit Holdings, Inc. (formerly known as Virgin Orbit) (such business combination, the "Business Combination"), which closed on December 29, 2021. The reporting person resigned as a director of the Issuer upon consummation of the Business Combination. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 23:51 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 96,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000899243-21-024525 · doc4.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 96,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 15, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:33 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0000899243-20-017085 · doc4.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2020. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 17, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 00:23 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 227,272 | $1.10 | $249,999.20 |
DisclosureSEC source: 0000899243-20-015869 · doc4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,460 F1 · shares: Reflects 227,272 shares that the were purchased by the Reporting Person directly from the underwriter in an underwritten public offering conducted by the Issuer. Read SEC document |
| September 13, 2019 Filed Sep 16, 2019 20:55 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 25,000 | $0.97 | $24,255.00 |
DisclosureSEC source: 0000899243-19-023645 · doc4.xml · nonDerivative · entry 2 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,188 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9360 per share to $0.99 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 20:55 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 88,145 | $0.98 | $86,249.88 |
DisclosureSEC source: 0000899243-19-023645 · doc4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,188 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8608 per share to $1.05 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 20:09 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 23,225 | $0.71 | $16,582.65 |
DisclosureSEC source: 0000899243-19-022827 · doc4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,043 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.68 per share to $0.7486 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 20:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 13,466 | $0.70 | $9,427.55 |
DisclosureSEC source: 0000899243-19-022724 · doc4.xml · nonDerivative · entry 2 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,818 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6805 per share to $0.7204 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 20:14 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 15,000 | $0.73 | $10,968.00 |
DisclosureSEC source: 0000899243-19-022724 · doc4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,352 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7155 per share to $0.75 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 21:17 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 3,600 | $0.77 | $2,770.92 |
DisclosureSEC source: 0000899243-19-022676 · doc4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,352 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.76 per share to $0.77 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 19, 2019 Filed Jun 24, 2019 21:23 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0000899243-19-017968 · doc4.xml · derivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: This option was granted on June 19, 2019. The shares underlying the option are scheduled to vest in equal annual installments over three years from June 19, 2019. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 9,000 | $88.10 Strike: $0.00 | $792,900.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 15 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2017-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 5,700 | $88.10 Strike: $0.00 | $502,170.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 14 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 5,700 shares Expires 2018-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. F12 · derivative.exercise_date: These restricted stock units were to vest in full on 09/09/2018. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 21,015 | $88.10 Strike: $0.00 | $1,851,421.50 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 13 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,015 shares Expires 2017-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 15,960 | $88.10 Strike: $0.00 | $1,406,076.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 12 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,015 Underlying: Common Stock · 15,960 shares Expires 2017-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 14,800 | $88.10 Strike: $0.00 | $1,303,880.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 11 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,800 shares Expires 2018-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. F10 · derivative.exercise_date: These restricted stock units were to vest in full on September 9, 2018. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 11,988 | $88.10 Strike: $0.00 | $1,056,142.80 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 10 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Underlying: Common Stock · 11,988 shares Expires 2017-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. F11 · derivative.exercise_date: These restricted stock units were to vest in full on 09/14/2019. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 29,600 | $88.10 Strike: $0.00 | $2,607,760.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 9 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires 2017-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherRestricted Stock Units · Derivative | 29,600 | $88.10 Strike: $0.00 | $2,607,760.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 8 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires 2017-12-31 F9 · kind: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each Company RSU Award, whether or not vested, was assumed by West Street Parent, LLC or the Company, cancelled and exchanged for the right to receive an amount in cash equal to the product obtained by multiplying (i) the aggregate number of shares of Company Common Stock subject to such award by (ii) the Merger Consideration. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherStock Options (Right to Buy) · Derivative | 151,700 | $67.84 Strike: $20.26 | $10,291,328.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 7 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 151,700 shares Expires 2019-09-21 F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F8 · derivative.exercise_date: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/21/2011. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherStock Options (Right to Buy) · Derivative | 108,800 | $57.46 Strike: $30.64 | $6,251,648.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 6 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,800 shares Expires 2020-09-19 F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F7 · derivative.exercise_date: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/19/2012. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherStock Options (Right to Buy) · Derivative | 73,500 | $39.41 Strike: $48.69 | $2,896,635.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 5 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,500 shares Expires 2021-09-11 F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F6 · derivative.exercise_date: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/11/2013. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherStock Options (Right to Buy) · Derivative | 93,300 | $30.17 Strike: $57.93 | $2,814,861.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 4 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,300 shares Expires 2022-09-10 F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F5 · derivative.exercise_date: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/10/2014. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherStock Options (Right to Buy) · Derivative | 95,000 | $21.52 Strike: $66.58 | $2,044,400.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 3 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,000 shares Expires 2023-09-09 F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F4 · derivative.exercise_date: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/09/2015. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | OtherStock Options (Right to Buy) · Derivative | 50,800 | $21.10 Strike: $67.00 | $1,071,880.00 |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · derivative · entry 2 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,800 shares Expires 2024-09-14 F2 · kind: Pursuant to the terms of the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017, each Company Stock Option, whether or not vested or exercisable, automatically converted into the right to receive an amount in cash equal to the product obtained by multiplying (i) the excess of the Merger Consideration over the per share exercise price of such Company Stock Option, by (ii) the aggregate number of shares of Company Common Stock issuable upon exercise of settlement of such Company Stock Option prior to the Effective Time. F3 · derivative.exercise_date: Options become exercisable in increments of 25% of the total shares granted, which commenced on the first anniversary of 09/14/2016. Read SEC document |
| September 29, 2017 Filed Oct 4, 2017 20:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Disposition to issuerCommon Stock | 503,329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-023611 · doc4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). F1 · price: Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the "Merger Agreement"), whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the "Merger Consideration"). Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 12:07 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Tax withholdingCommon Stock | 4,642 | $87.93 | $408,171.06 |
DisclosureSEC source: 0001127602-17-027561 · form4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,329 Read SEC document |
| September 11, 2017 Filed Sep 12, 2017 13:15 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Tax withholdingCommon Stock | 15,402 | $87.77 | $1,351,833.54 |
DisclosureSEC source: 0001127602-17-027310 · form4.xml · nonDerivative · entry 3 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,971 F1 · balance_after: Includes 507 shares of common stock acquired pursuant to the Issuer's 2000 Employee Stock Purchase Plan. Read SEC document |
| September 10, 2017 Filed Sep 12, 2017 13:15 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Exercise / conversionRestricted Stock Units · Derivative | 9,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027310 · form4.xml · derivative · entry 7 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PAREXEL International Corporation common stock. F3 · derivative.expiration_date: The restricted stock units awarded pursuant to the PAREXEL International Corporation 2010 Stock Incentive Plan will vest in full on September 10, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, and in any event no later than December 31, 2017. Read SEC document |
| September 10, 2017 Filed Sep 12, 2017 13:15 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Exercise / conversionCommon Stock | 9,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027310 · form4.xml · nonDerivative · entry 2 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 13:15 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantRestricted Stock Units · Derivative | 2,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027310 · form4.xml · derivative · entry 6 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,812 Underlying: Common Stock · 2,812 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PAREXEL International Corporation common stock. F5 · derivative.expiration_date: These restricted stock units awarded pursuant to the PAREXEL International Corporation 2015 Stock Incentive Plan will vest in full on September 14, 2019 subject to the satisfaction of certain performance criteria. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, and in any event no later than December 31, 2019. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 13:15 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantRestricted Stock Units · Derivative | 1,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027310 · form4.xml · derivative · entry 5 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,055 Underlying: Common Stock · 1,755 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PAREXEL International Corporation common stock. F4 · derivative.expiration_date: The restricted stock units awarded pursuant to the PAREXEL International Corporation Stock Incentive Plans will vest in full on September 9, 2018. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, and in any event no later than December 31, 2018. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 13:15 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantRestricted Stock Units · Derivative | 2,028 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027310 · form4.xml · derivative · entry 4 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,308 Underlying: Common Stock · 2,028 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PAREXEL International Corporation common stock. F3 · derivative.expiration_date: The restricted stock units awarded pursuant to the PAREXEL International Corporation 2010 Stock Incentive Plan will vest in full on September 10, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, and in any event no later than December 31, 2017. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 13:15 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GiftCommon Stock | 22,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027310 · form4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,065 Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 16:08 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantRestricted Stock Units · Derivative | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-062666 · form4.xml · derivative · entry 4 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 Underlying: Common Stock · 3,300 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PAREXEL International Corporation common stock. F5 · derivative.expiration_date: The restricted stock units awarded pursuant to the PAREXEL International Corporation Stock Incentive Plans will vest in full on September 9, 2018. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, and in any event no later than December 31, 2018. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 16:08 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantRestricted Stock Units · Derivative | 4,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-062666 · form4.xml · derivative · entry 3 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,280 Underlying: Common Stock · 4,420 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PAREXEL International Corporation common stock. F4 · derivative.expiration_date: The restricted stock units awarded pursuant to the PAREXEL International Corporation 2010 Stock Incentive Plan will vest in full on September 10, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, and in any event no later than December 31, 2017. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 16:08 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantStock Option (Right to Buy) · Derivative | 50,800 | $0.00 Strike: $67.00 | $0.00 |
DisclosureSEC source: 0001127602-16-062666 · form4.xml · derivative · entry 2 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,800 Underlying: Common Stock · 50,800 shares Expires 2024-09-14 F2 · derivative.exercise_date: Options become exercisable in increments of 25% of the total shares granted commencing on the first anniversary of the date of grant. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 16:08 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | GrantCommon Stock | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-062666 · form4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,353 F1 · security: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 09:35 UTC | PAREXEL INTERNATIONAL CORP PRXL · Entity 172709 | Tax withholdingCommon Stock | 14,743 | $66.54 | $980,999.22 |
DisclosureSEC source: 0001127602-16-062490 · form4.xml · nonDerivative · entry 1 VON RICKENBACH JOSEF H · CIK 0001007706 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,753 F1 · balance_after: Includes 366 shares of common stock acquired pursuant to the Issuer's 2000 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.